Literature DB >> 8453958

Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population.

B Klemetsdal1, B Straume, E Wist, J Aarbakke.   

Abstract

Red blood cell (RBC) thiopurine methyltransferase (TPMT), an inactivating pathway of 6-mercaptopurine, is controlled by genetic polymorphism and is subject to ethnic variation. RBC TPMT is a good predictor of clinical outcome in children with acute lymphoblastic leukemia. RBC TPMT activity was determined in 226 patients, 176 of them living in northern Norway (of which 123 were Saami (Lapps)). Demographic variables, use of drugs and presence of chronic diseases were evaluated as possible predictors of RBC TPMT activity by a multiple regression model. Men had higher RBC TPMT activity compared to women. Living in the northernmost county of Norway was associated with increased RBC TPMT activity irrespective of ethnicity. The use of diuretics was associated with increased RBC TPMT activity. The gender difference in RBC TPMT activity may indicate a need to treat male subjects more aggressively with thiopurine drugs compared to female subjects.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453958     DOI: 10.1007/bf00315472

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  RELATIONSHIP BETWEEN AMBIENT TEMPERATURE AND ACETYLATING CAPACITY OF HUMAN BLOOD.

Authors:  S H BLONDHEIM; G NEUMANN; E KOTT; Z BEN-ISHAI
Journal:  J Appl Physiol       Date:  1963-09       Impact factor: 3.531

2.  [Reproduction pattern in the Lapps].

Authors:  J TORGERSEN
Journal:  Tidsskr Nor Laegeforen       Date:  1956-11-01

Review 3.  Variables and paradoxes in "maintenance" therapy of lymphoblastic leukemia.

Authors:  J S Lilleyman
Journal:  Pediatr Hematol Oncol       Date:  1991 Oct-Dec       Impact factor: 1.969

4.  Calculating confidence intervals for some non-parametric analyses.

Authors:  M J Campbell; M J Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

5.  Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties.

Authors:  R M Weinshilboum; F A Raymond; P A Pazmiño
Journal:  Clin Chim Acta       Date:  1978-05-02       Impact factor: 3.786

6.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.

Authors:  R M Weinshilboum; S L Sladek
Journal:  Am J Hum Genet       Date:  1980-09       Impact factor: 11.025

7.  Influence of sex and oral contraceptive steroids on paracetamol metabolism.

Authors:  J O Miners; J Attwood; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

8.  Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes.

Authors:  C L Szumlanski; R Honchel; M C Scott; R M Weinshilboum
Journal:  Pharmacogenetics       Date:  1992-08

9.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.

Authors:  W E Evans; M Horner; Y Q Chu; D Kalwinsky; W M Roberts
Journal:  J Pediatr       Date:  1991-12       Impact factor: 4.406

10.  Childhood lymphoblastic leukaemia: sex difference in 6-mercaptopurine utilization.

Authors:  J S Lilleyman; L Lennard; C A Rees; G Morgan; J L Maddocks
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

View more
  12 in total

1.  Thiopurine S-methyltransferase as a target for drug interactions.

Authors:  Hua-Wen Xin; Christine Fischer; Matthias Schwab; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

2.  Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.

Authors:  Margalida Calafat; Míriam Mañosa; Fiorella Cañete; Eugeni Domènech
Journal:  Drugs Aging       Date:  2021-01-13       Impact factor: 3.923

3.  Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide.

Authors:  R A Lysaa; T Giverhaug; H L Wold; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

4.  Purine enzyme activities in recent onset rheumatoid arthritis: are there differences between patients and healthy controls?

Authors:  J N Stolk; A M Boerbooms; R A De Abreu; P J Kerstens; D G de Koning; R de Graaf; J Mulder; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1996-10       Impact factor: 19.103

Review 5.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

7.  Erythrocyte fraction affects red blood cell thiopurine methyltransferase activity.

Authors:  B Klemetsdal; B Straume; R Lysaa; T Giverhaug; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.

Authors:  E Jacqz-Aigrain; E Bessa; Y Medard; Y Mircheva; E Vilmer
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

9.  Interactions between 6-mercaptopurine therapy and thiopurine-methyl-transferase (TPMT) activity.

Authors:  R Capdeville; B Mousson; G Bax; Y Bertrand; N Philippe
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Low catechol-O-methyltransferase activity in a Saami population.

Authors:  B Klemetsdal; B Straume; T Giverhaug; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.